Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells

SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear. In this research, ApoE−/− mice were fed with western diet and empagliflozin wa...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Junping Li, Changping Li, Zhaoqi Huang, Chunling Huang, Juanzhang Liu, Tao Wu, Shuwan Xu, Peibiao Mai, Dengfeng Geng, Shuxian Zhou, Kun Zhang, Zhaoyu Liu
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2023-11-01
Sarja:	Frontiers in Pharmacology
Aiheet:	atherosclerosis arterial calcification empagliflozin osteogenic differentiation vascular smooth muscle cell
Linkit:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1295463/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!